The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups
Open accessAbstract
Langerhans cell histiocytosis (LCH) is a clonal disorder with elusive etiology, characterized by the accumulation of CD207+ dendritic cells (DCs) in inflammatory lesions. Recurrent BRAF-V600E mutations have been reported in LCH. In this study, lesions from 100 patients were genotyped, and 64% carried the BRAF-V600E mutation within infiltrating CD207+ DCs. BRAF-V600E expression in tissue DCs did not define specific clinical risk groups but was associated with increased risk of recurrence. Strikingly, we found that patients with active, high-risk LCH also carried BRAF-V600E in circulating CD11c+ and CD14+ fractions and in bone marrow (BM) CD34+ hematopoietic cell progenitors, whereas the mutation was restricted to lesional CD207+ DC in low-risk LCH patients. Importantly, BRAF-V600E expression in DCs was sufficient to drive LCH-like disease in mice. Consistent with our findings in humans, expression of BRAF-V600E in BM DC progenitors recapitulated many features of the human high-risk LCH, whereas BRAF-V600E expression in differentiated DCs more closely resembled low-risk LCH. We therefore propose classification of LCH as a myeloid neoplasia and hypothesize that high-risk LCH arises from somatic mutation of a hematopoietic progenitor, whereas low-risk disease arises from somatic mutation of tissue-restricted precursor DCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074950 · Cited by 2,309
Recurrent BRAF mutations in Langerhans cell histiocytosis
Badalian-Very, G., Vergilio, J.-A., Degar, B. A., MacConaill, L. E., Brandner, B., Calicchio, M. L., Kuo, F. C., Ligon, A. H., Stevenson, K. E., Kehoe, S. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279083 · Cited by 1,243
Biology of Hematopoietic Stem Cells and Progenitors: Implications for Clinical Application
Kondo, M., Wagers, A. J., Manz, M. G., Prohaska, S. S., Scherer, D. C., Beilhack, G. F., Shizuru, J. A., & Weissman, I. L. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141007 · Cited by 997
Self-citationLangerhans'-Cell Histiocytosis (Histiocytosis X) -- A Clonal Proliferative Disease
Willman, C. L., Busque, L., Griffith, B. B., Favara, B. E., McClain, K. L., Duncan, M. H., & Gilliland, D. G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199407213310303 · Cited by 994
Self-citationValladeau, J., Ravel, O., Dezutter-Dambuyant, C., Moore, K., Kleijmeer, M., Liu, Y., Duvert-Frances, V., Vincent, C., Schmitt, D., Davoust, J., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)80160-0 · Cited by 962
Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells
Merad, M., Ginhoux, F., & Collin, M. (2008) · Nature Reviews Immunology · doi:10.1038/nri2455 · Cited by 850
Self-citationBirbeck, M. S., Breathnach, A. S., & Everall, J. D. (1961) · Journal of Investigative Dermatology · doi:10.1038/jid.1961.80 · Cited by 806
Haroche, J., Charlotte, F., Arnaud, L., von Deimling, A., Hélias-Rodzewicz, Z., Hervier, B., Cohen-Aubart, F., Launay, D., Lesot, A., Mokhtari, K., et al. (2012) · Blood · doi:10.1182/blood-2012-05-430140 · Cited by 696
Haroche, J., Cohen-Aubart, F., Emile, J.-F., Arnaud, L., Maksud, P., Charlotte, F., Cluzel, P., Drier, A., Hervier, B., Benameur, N., et al. (2013) · Blood · doi:10.1182/blood-2012-07-446286 · Cited by 537
Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 481
Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state
Ginhoux, F., Collin, M. P., Bogunovic, M., Abel, M., Leboeuf, M., Helft, J., Ochando, J., Kissenpfennig, A., Malissen, B., Grisotto, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071733 · Cited by 420
Self-citationClonal proliferation of Langerhans cells in Langerhans cell histiocytosis
Yu, R. C., Chu, A. C., Chu, C., & Buluwela, L. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91842-2 · Cited by 388
CENTRAL NERVOUS SYSTEM DISEASE IN LANGERHANS CELL HISTIOCYTOSIS
Grois, N. G., Favara, B. E., Mostbeck, G. H., & Prayer, D. (1998) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70511-6 · Cited by 347
Histiocytosis X histogenetic arguments for a Langerhans cell origin.
Nézelof, C., Basset, F., & Rousseau-Merck, M. F. (1973) · PubMed · Cited by 330
Allen, C. E., Li, L., Peters, T. L., Leung, H.-C. E., Yu, A., Man, T.-K., Gurusiddappa, S., Phillips, M. T., Hicks, M. J., Gaikwad, A., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902336 · Cited by 326
Self-citationCentral Nervous System Disease in Langerhans Cell Histiocytosis
Grois, N., Fahrner, B., Arceci, R. J., Henter, J.-I., McClain, K., Lassmann, H., Nanduri, V., Prosch, H., & Prayer, D. (2010) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2010.03.001 · Cited by 261
Self-citationZelickson, A. S., & Hartmann, J. F. (1961) · Journal of Investigative Dermatology · doi:10.1038/jid.1961.7 · Cited by 233
Sahm, F., Capper, D., Preusser, M., Meyer, J., Stenzinger, A., Lasitschka, F., Berghoff, A.-S., Habel, A., Schneider, M., Kulozik, A., et al. (2012) · Blood · doi:10.1182/blood-2012-06-429597 · Cited by 221
Satoh, T., Smith, A., Sarde, A., Lu, H., Mian, S., Trouillet, C., Mufti, G. J., Emile, J., Fraternali, F., Donadieu, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033891 · Cited by 166
Expansion of Regulatory T Cells in Patients with Langerhans Cell Histiocytosis
Sénéchal, B., Elain, G., Jeziorski, É., Grondin, V., Patey, N., Jaubert, F., Beldjord, K., Lellouch‐Tubiana, A., Glorion, C., Zérah, M., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040253 · Cited by 152
Chikwava, K. R., & Jaffe, R. (2004) · Pediatric and Developmental Pathology · doi:10.1007/s10024-004-3027-z · Cited by 144
da Costa, C. E. T., Annels, N. E., Faaij, C. M. J. M., Forsyth, R. G., Hogendoorn, P. C. W., & Egeler, R. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041785 · Cited by 134
The histiocytoses: The fall of the Tower of Babel
Arceci, R. J. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00039-8 · Cited by 126
Kissenpfennig, A., Aït‐Yahia, S., Clair‐Moninot, V., Stössel, H., Badell, E., Bordat, Y., Pooley, J. L., Lang, T., Prina, E., Coste, I., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.88-99.2005 · Cited by 117
THE PRESENCE OF CYTOKINES IN LANGERHANS' CELL HISTIOCYTOSIS
de Graaf, J. H., Tamminga, R., Dam‐Meiring, A., Kamps, W. A., & Timens, W. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199612)180:4<400::aid-path701>3.0.co;2-w · Cited by 105
Zahner, S. P., Kel, J. M., Martina, C. A. E., Brouwers-Haspels, I., van ROON, M. A., & Clausen, B. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101880 · Cited by 81
Self-citationKansal, R., Quintanilla‐Martínez, L., Datta, V., Lopategui, J. R., Garshfield, G., & Nathwani, B. N. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22010 · Cited by 68
Verdijk, P., Dijkman, R., Plasmeijer, E. I., Mulder, A. A., Zoutman, W. H., Mommaas, A. M., & Tensen, C. P. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23645.x · Cited by 51
Chang, S., Cha, H., Chang, J., Ko, H., Yang, H., MALISSEN, B., Iwata, M., & Kweon, M. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.11.006 · Cited by 46
Verma, S., Greaves, W. O., Ravandi, F., Reddy, N., Bueso-Ramos, C., O'Brien, S. M., Thomas, D. A., Kantarjian, H. M., Medeiros, L. J., Luthra, R., et al. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpl0opxi9lzitv · Cited by 38
Cited by
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
Emile, J.-F., Abla, O., Fraitag, S., Horne, A., Haroche, J., Donadieu, J., Requena-Caballero, L., Jordan, M. B., Abdel-Wahab, O., Allen, C. E., et al. (2016) · Blood · doi:10.1182/blood-2016-01-690636 · Cited by 1,591
Self-citationAutophagy in malignant transformation and cancer progression
Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490784 · Cited by 1,182
Allen, C. E., Merad, M., & McClain, K. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1607548 · Cited by 570
Self-citationDiverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Diamond, E. L., Durham, B. H., Haroche, J., Yao, Z., Ma, J., Parikh, S. A., Wang, Z., Choi, J., Kim, E., Cohen-Aubart, F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0913 · Cited by 535
Chakraborty, R., Hampton, O. A., Shen, X., Simko, S. J., Shih, A., Abhyankar, H., Lim, K. P. H., Covington, K. R., Trevino, L., Dewal, N., et al. (2014) · Blood · doi:10.1182/blood-2014-05-577825 · Cited by 431
Self-citation
Metadata
- Authors
- Berres, M.-L., Lim, K. P. H., Peters, T., Price, J., Takizawa, H., Salmon, H., Idoyaga, J., Ruzo, A., Lupo, P. J., Hicks, M. J., Shih, A., Simko, S. J., Abhyankar, H., Chakraborty, R., Leboeuf, M., Beltrão, M., Lira, S. A., Heym, K. M., Clausen, B. E., Bigley, V., Collin, M., Manz, M. G., McClain, K., Merad, M., & Allen, C. E.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-03-17
- Volume
- 211
- Issue
- 4
- Pages
- 669-683
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2161282095
- Cited by
- 442
- References
- 31
- FWCI
- 25.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.